Multitarget antileukemic effects of metformin in myeloproliferative neoplasm cells: inhibition of JAK2/STAT signaling and mitochondrial activity (2016)
- Authors:
- Machado Neto, João Agostinho
- Fenerich, Bruna Alves
- Scopim-Ribeiro, Renata
- Dechandt, Carlos Roberto Porto
- Alves, Ana Paula Nunes Rodrigues
- Fernandes, Jaqueline Cristina
- Scheucher, Priscila Santos
- Simões, Belinda Pinto
- Alberici, Luciane Carla
- Pontes, Lorena Lôbo de Figueiredo
- Rego, Eduardo Magalhães
- Traina, Fabiola
- Machado Neto, João Agostinho
- USP affiliated authors: SIMOES, BELINDA PINTO - FMRP ; REGO, EDUARDO MAGALHÃES - FMRP ; TRAINA, FABÍOLA - FMRP ; SCHEUCHER, PRISCILA SANTOS - FMRP ; ALBERICI, LUCIANE CARLA - FCFRP
- Unidades: FMRP; FCFRP
- Subjects: CLÍNICA GERAL; LEUCEMIA MIELOIDE; INSULINA
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Abstracts
- Conference titles: Annual Meeting and Exposition of the American Society of Hematology
-
ABNT
MACHADO NETO, João Agostinho et al. Multitarget antileukemic effects of metformin in myeloproliferative neoplasm cells: inhibition of JAK2/STAT signaling and mitochondrial activity. 2016, Anais.. San Diego: ASH, 2016. Disponível em: http://www.bloodjournal.org/content/128/22/1960. Acesso em: 24 abr. 2024. -
APA
Machado Neto, J. A., Fenerich, B. A., Scopim-Ribeiro, R., Dechandt, C. R. P., Alves, A. P. N. R., Fernandes, J. C., et al. (2016). Multitarget antileukemic effects of metformin in myeloproliferative neoplasm cells: inhibition of JAK2/STAT signaling and mitochondrial activity. In Abstracts. San Diego: ASH. Recuperado de http://www.bloodjournal.org/content/128/22/1960 -
NLM
Machado Neto JA, Fenerich BA, Scopim-Ribeiro R, Dechandt CRP, Alves APNR, Fernandes JC, Scheucher PS, Simões BP, Alberici LC, Pontes LL de F, Rego EM, Traina F. Multitarget antileukemic effects of metformin in myeloproliferative neoplasm cells: inhibition of JAK2/STAT signaling and mitochondrial activity [Internet]. Abstracts. 2016 ;[citado 2024 abr. 24 ] Available from: http://www.bloodjournal.org/content/128/22/1960 -
Vancouver
Machado Neto JA, Fenerich BA, Scopim-Ribeiro R, Dechandt CRP, Alves APNR, Fernandes JC, Scheucher PS, Simões BP, Alberici LC, Pontes LL de F, Rego EM, Traina F. Multitarget antileukemic effects of metformin in myeloproliferative neoplasm cells: inhibition of JAK2/STAT signaling and mitochondrial activity [Internet]. Abstracts. 2016 ;[citado 2024 abr. 24 ] Available from: http://www.bloodjournal.org/content/128/22/1960 - Pharmacological IGF1R/IRS inhibitor, NT157, effectively induces apoptosis and CDKN1A expression in acute lymphoblastic leukemia cells
- Reversine triggers mitotic catastrophe and apoptosis in K562 cells
- Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms
- Pharmacological IRS1/2 inhibition induces apoptosis in BCR-ABL1T315I mutant cells
- Reversine triggers mitotic catastrophe and apoptosis in BCR-ABL positive cells
- Activation of IRS1/beta-catenin axis in acute lymphoblastic leukemia
- IRS1/β-catenin axis is activated and induces MYC expression in acute lymphoblastic leukemia cells
- Paclitaxel induces Stathmin 1 phosphorylation, microtubule stability and apoptosis in acute lymphoblastic leukemia cells
- The pharmacological IGF1R-IRS1/2 inhibitor NT157 presents multiple anti-neoplastic effects in myeloproliferative neoplasms
- Stathmin 1 é altamente expressa em leucemia promielocítica aguda e a dinâmica dos microtúbulos é um alvo potencial para células PML-RAR resistentes ao atra
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
